1,124 results on '"Northcott, Paul A"'
Search Results
152. DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma
153. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
154. Active medulloblastoma enhancers reveal subgroup-specific cellular origins
155. Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas
156. Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
157. MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma
158. INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.
159. ETMR-14. The single-cell landscape of pineoblastoma identifies developmental origins and exposes novel therapeutic vulnerabilities.
160. Low-coverage whole-genome sequencing of cerebrospinal-fluid-derived cell-free DNA in brain tumor patients
161. MEDB-42. GermlineElp1 deficiency promotes genomic instability and survival of granule neuron progenitors primed for SHH medulloblastoma pathogenesis
162. MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?
163. MEDB-82. Exploring cell-cell communication networks in medulloblastoma using single-cell genomics
164. MEDB-74. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies
165. MEDB-69. Clinical and molecular meta-analysis of three major medulloblastoma clinical trials (ACNS0331, SJMB03, ACNS0332) uncovers novel strategies to improve risk-stratified therapy
166. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis
167. The RNA-Binding Protein Musashi1 Affects Medulloblastoma Growth via a Network of Cancer-Related Genes and Is an Indicator of Poor Prognosis
168. Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas
169. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers
170. Medulloblastoma subgroups remain stable across primary and metastatic compartments
171. Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC
172. Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumor
173. An Animal Model of MYC-Driven Medulloblastoma
174. Author Correction: scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy
175. The Genetic Landscape of the Childhood Cancer Medulloblastoma
176. Bridging Courses by Distance Education for Overseas-Trained Professionals Migrating to Australia: Practical and Viability Issues.
177. FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma
178. Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma
179. Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility
180. Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026)
181. Mapping pediatric brain tumors to their origins in the developing cerebellum
182. Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study
183. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity
184. Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts
185. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort
186. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group
187. Divergent clonal selection dominates medulloblastoma at recurrence
188. Designing an MBA Curriculum for Information Systems Managers: An Analysis of Contextual Factors
189. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system
190. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
191. BIOM-36. SERIAL ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN MEDULLOBLASTOMA LIQUID BIOPSIES
192. EPCO-26. INTEGRATIVE MULTI-OMICS IDENTIFIES CONVERGING DEVELOPMENTAL ORIGINS OF DISTINCT MEDULLOBLASTOMA SUBGROUPS
193. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies
194. Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma
195. DNA methylation-based classification of central nervous system tumours
196. The landscape of genomic alterations across childhood cancers
197. Author Correction: The landscape of genomic alterations across childhood cancers
198. Keeping it real to kill glioblastoma
199. Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays
200. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.